← Leaderboards
Amy Beth Heimberger
Northwestern University
$11,078,637
Attributed
$15,588,422
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2007–25$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,588,422 · 9
By mechanism
R01$12,286,453 · 5
P50$3,259,131 · 3
P30$42,838 · 1
Top collaborators
- Shulin Li10 shared
- Ganesh Rao5 shared
- Priya U. Kumthekar3 shared
- Arvind Rao3 shared
Most similar at Northwestern University
Same institution · by research overlap
- Arvind Rao$2,993,102
- Andrew M Evens$3,800,221
- Athanassios Argiris$721,909
Others in their field
Top investigators on “Immune”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmuneTumorImmunotherapyMediatingGliomaResponseGlioblastomaT-LymphocyteClinical TrialsImmune ResponseBrainCellsMalignant NeoplasmsBaseGrowthNeuraxisPathway InteractionsIn VivoRecurrenceImmune SystemNatural ImmunityNeoplastic CellPreventMalignant Glioma
Grant awards (49)
A Phase II Clinical Trial in Newly Diagnosed Glioblastoma Patients Treated with WP1066 and Radiation$598,126
R01 · FY2025 · CA · contact PI
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse$589,497
R01 · FY2025 · NS
STINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBM$347,923
P50 · FY2025 · CA · contact PI
Modulation of Microglia and T Cell Interactions in Malignant Glioma$287,999
R01 · FY2025 · CA · contact PI
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse$571,813
R01 · FY2024 · NS
A Phase II Clinical Trial in Newly Diagnosed Glioblastoma Patients Treated with WP1066 and Radiation$568,219
R01 · FY2024 · CA · contact PI
STINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBM$312,874
P50 · FY2024 · CA · contact PI
Modulation of Microglia and T Cell Interactions in Malignant Glioma$273,600
R01 · FY2024 · CA · contact PI
A Phase II Clinical Trial in Newly Diagnosed Glioblastoma Patients Treated with WP1066 and Radiation$601,792
R01 · FY2023 · CA · contact PI
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse$589,497
R01 · FY2023 · NS
Stinging the Glioma Immune Landscape$324,017
R01 · FY2023 · NS · contact PI
Modulation of Microglia and T Cell Interactions in Malignant Glioma$287,999
R01 · FY2023 · CA · contact PI
STINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBM$285,775
P50 · FY2023 · CA · contact PI
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse$589,497
R01 · FY2022 · NS
Stinging the Glioma Immune Landscape$341,138
R01 · FY2022 · NS · contact PI
Modulation of Microglia and T Cell Interactions in Malignant Glioma$282,238
R01 · FY2022 · CA · contact PI
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse$604,997
R01 · FY2021 · NS
Modulation of Microglia and T Cell Interactions in Malignant Glioma$302,654
R01 · FY2021 · CA · contact PI
Stinging the Glioma Immune Landscape$387,468
R01 · FY2020 · NS · contact PI
Fgl-2 targeted therapy for reversing multi-modality immune suppression$366,000
R01 · FY2020 · CA
05 Brain Cancer$18,675
P30 · FY2020 · CA · contact PI
Fgl-2 targeted therapy for reversing multi-modality immune suppression$355,019
R01 · FY2019 · CA
05 Brain Cancer$18,707
P30 · FY2019 · CA · contact PI
05 Brain Cancer$5,456
P30 · FY2019 · CA · contact PI
Fgl-2 targeted therapy for reversing multi-modality immune suppression$366,000
R01 · FY2018 · CA
Modulation of Microglia and T Cell Interactions in Malignant Glioma$288,000
R01 · FY2018 · CA · contact PI
Fgl-2 targeted therapy for reversing multi-modality immune suppression$366,000
R01 · FY2017 · CA
Modulation of Microglia and T Cell Interactions in Malignant Glioma$288,000
R01 · FY2017 · CA · contact PI
Targeting Malignant Gliomas with a Novel Inhibitor of the STAT3 Pathway$263,896
P50 · FY2017 · CA · contact PI
Fgl-2 targeted therapy for reversing multi-modality immune suppression$366,000
R01 · FY2016 · CA
Modulation of Microglia and T Cell Interactions in Malignant Glioma$288,000
R01 · FY2016 · CA · contact PI
Targeting Malignant Gliomas with a Novel Inhibitor of the STAT3 Pathway$247,990
P50 · FY2016 · CA · contact PI
Modulation of Microglia and T Cell Interactions in Malignant Glioma$288,000
R01 · FY2015 · CA · contact PI
Targeting Malignant Gliomas with a Novel Inhibitor of the STAT3 Pathway$251,137
P50 · FY2015 · CA · contact PI
Modulation of Microglia and T Cell Interactions in Malignant Glioma$288,000
R01 · FY2014 · CA · contact PI
Targeting Malignant Gliomas with a Novel Inhibitor of the STAT3 Pathway$245,325
P50 · FY2014 · CA · contact PI
Effects of a Novel Phospho-STAT2 inhibitor for Treatment of Stage IV Melanoma$174,693
P50 · FY2014 · CA · contact PI
Effects of a Novel Phospho-STAT2 inhibitor for Treatment of Stage IV Melanoma$277,339
P50 · FY2013 · CA · contact PI
Modulation of Microglia and T Cell Interactions in Malignant Glioma$247,317
R01 · FY2013 · CA · contact PI
Targeting Malignant Gliomas with a Novel Inhibitor of the STAT3 Pathway$245,058
P50 · FY2013 · CA · contact PI
Modulation of Microglia and T Cell Interactions in Malignant Glioma$263,103
R01 · FY2012 · CA · contact PI
Effects of a Novel Phospho-STAT2 inhibitor for Treatment of Stage IV Melanoma$225,296
P50 · FY2012 · CA · contact PI
Modulation of Microglia and T Cell Interactions in Malignant Glioma$263,103
R01 · FY2011 · CA · contact PI
Effects of a Novel Phospho-STAT2 inhibitor for Treatment of Stage IV Melanoma$186,434
P50 · FY2011 · CA · contact PI
Modulation of Microglia and T Cell Interactions in Malignant Glioma$263,340
R01 · FY2010 · CA · contact PI
Effects of a Novel Phospho-STAT2 inhibitor for Treatment of Stage IV Melanoma$195,391
P50 · FY2010 · CA · contact PI
Modulation of Microglia and T Cell Interactions in Malignant Glioma$263,340
R01 · FY2009 · CA · contact PI
Modulation of Microglia and T Cell Interactions in Malignant Glioma$263,340
R01 · FY2008 · CA · contact PI
Modulation of Microglia and T Cell Interactions in Malignant Glioma$263,340
R01 · FY2007 · CA · contact PI